NCT03002805UnknownPhase 1
A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin
CBA Research12 sites in 1 country46 target enrollmentStarted: March 29, 2018Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 46
- Locations
- 12
- Primary Endpoint
- Maximum tolerated dose of CBT-1® when combined with doxorubicin
Study Overview
Brief Summary
This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •Locally advanced or metastatic, unresectable sarcoma that has progressed after treatment with 150 mg/m2 or less of doxorubicin or anthracycline equivalent
- •Measurable disease by RECIST 1.1
- •ECOG performance status of ≤ 1
- •Life expectancy of > 3 months
- •Able to swallow pills
- •Adequate bone marrow and organ function as defined as:
- •Hemoglobin > 9 g/dl
- •Absolute neutrophil count ≥ 1,500/mcL
- •Platelets ≥ 100,000/mcL
- •Total bilirubin < 1.5 X ULN
- •AST(SGOT)/ALT(SGPT) ≤3 X ULN (including patients with liver metastases)
- •Creatinine <1.5 X ULN
- •Cardiac ejection fraction >50% (by echocardiogram or MUGA) within 15 days of enrollment
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment.
- •Participants must be willing and able to comply with the study scheduled visits, laboratory tests, and other procedures outlined in the protocol.
- •Pre-menopausal women must have a negative pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation. Acceptable methods of contraception include intrauterine device (IUD), oral contraceptive, subdermal implant, double barrier and/or complete abstinence (non-periodic).
- •Washout period prior to Day 1 Cycle 1:
- •3 weeks since last chemotherapy or therapeutic radiation therapy
- •4 weeks or 3 half-lives since prior antibody-based therapy, whichever is shorter
- •2 weeks since any oral anti-neoplastic or oral investigational agent
- •Resolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity are allowed < grade 2
- •>1 week since palliative RT
- •Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
- •Prior exposure to CBT-1
- •Previously untreated sarcomas
- •Low-grade sarcomas as well as alveolar soft parts sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, well-differentiated liposarcoma, gastrointestinal stromal tumor, chordoma
- •Participants receiving other investigational agents
- •Participants with known uncontrolled brain metastases
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic indwelling drains, history of interstitial pneumonitis or pulmonary fibrosis or psychiatric illness/social situations that would limit compliance with study requirements
- •Actively breastfeeding women unless it is interrupted during treatment and at least 6 weeks after treatment discontinuation
Outcomes
Primary Outcomes
Maximum tolerated dose of CBT-1® when combined with doxorubicin
Time Frame: 3 years
Secondary Outcomes
- Overall Response Rate(3 years)
- Disease Control Rate (DCR) of CBT-1® when combined with doxorubicin(week 12)
- Recommended phase 2 dose (RP2D) of CBT-1® when combined with doxorubicin(3 years)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Terminated
Phase 1
Bortezomib and Docetaxel in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00049088National Cancer Institute (NCI)24
Terminated
Phase 2
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast CancerMetastatic Breast CancerNCT00574236University of Wisconsin, Madison4
Completed
Phase 2
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaMultiple MyelomaNCT00872521Janssen-Cilag Pty Ltd107
Completed
Phase 1
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasAdult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Mixed Cell LymphomaStage III Adult Diffuse Small Cleaved Cell LymphomaStage III Adult Hodgkin LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Adult Lymphoblastic LymphomaStage III Adult T-cell Leukemia/LymphomaStage III Cutaneous T-cell Non-Hodgkin LymphomaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Mantle Cell LymphomaStage III Marginal Zone LymphomaStage III Mycosis Fungoides/Sezary SyndromeStage III Small Lymphocytic LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Mixed Cell LymphomaStage IV Adult Diffuse Small Cleaved Cell LymphomaStage IV Adult Hodgkin LymphomaStage IV Adult Immunoblastic Large Cell LymphomaStage IV Adult Lymphoblastic LymphomaStage IV Adult T-cell Leukemia/LymphomaStage IV Cutaneous T-cell Non-Hodgkin LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaStage IV Marginal Zone LymphomaStage IV Mycosis Fungoides/Sezary SyndromeStage IV Small Lymphocytic LymphomaUnspecified Adult Solid Tumor, Protocol SpecificWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT00348985National Cancer Institute (NCI)55
Terminated
Phase 1
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT05156905University of California, San Diego6